CAMBRIDGE, MA, October 16, 2017 - PROMETRIKA, LLC, a boutique full service Clinical Research Organization (CRO), is coordinating a Phase 1 trial for The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science. PROMETRIKA is responsible for the clinical trial management and site monitoring, medical monitoring, database implementation and data management, pharmacovigilance, biostatistics, and medical writing for this advanced solid tumors and lymphoma trial.
“We are excited to work on a second Phase I trial with the institution as it works to end cancer,” said Miganush Stepanians, Ph.D., President and CEO of PROMETRIKA.
This study presents another opportunity for PROMETRIKA to leverage its considerable expertise and experience in Phase 1 oncology trials and to contribute to the ongoing fight against cancer.